Edwards Lifesciences (NYSE: EW) reported Q2 EPS of $0.66, $0.01 better than the analyst estimate of $0.65. Revenue for the quarter came in at $1.53 billion versus the consensus estimate of $1.5 billion.

For earnings history and earnings-related data on Edwards Lifesciences (EW) click here.